Biogen Shifts Strategy Beyond Neurology With 10 Phase III Readouts on the Horizon

Biotechnology major Biogen Inc. (NASDAQ: BIIB) is executing a strategic pivot away from its historical concentration in neurology, advancing a late-stage pipeline that now includes 10 Phase III clinical initiatives with initial trial readouts scheduled to begin in the fourth quarter, according to executive remarks first reported by Yahoo Finance. The Cambridge, Massachusetts-based company is working to diversify its revenue streams into immunology and nephrology to mitigate continuing sales contraction across its legacy multiple sclerosis treatments.

Speaking at a recent Wells Fargo healthcare investor conference, Biogen Chief Financial Officer Robin Kramer and Head of Corporate Development Adam Keeney detailed how the enterprise is reshaping its operational footprint. Kramer noted that the firm's portfolio of newer commercial products—including Alzheimer's therapy Leqembi, Friedreich's ataxia treatment Skyclarys, and postpartum depression drug Zurzuvae—has successfully counterbalanced the financial erosion in its legacy multiple sclerosis franchise across most quarters in 2025. During the second quarter, sales from these expansion products, excluding contributions from newly integrated assets, surpassed total revenue generated by the legacy multiple sclerosis line.

A central pillar of Biogen's expansion beyond traditional neurology is its acquisition of HI-Bio, which brought the monoclonal antibody felzartamab into its clinical pipeline. Keeney highlighted antibody-mediated rejection (AMR) in kidney transplant recipients as the foundational indication for the drug. Approximately 11,000 patients in the United States suffer from secondary rejection of kidney transplants annually, a condition with no currently approved therapeutic options. Beyond AMR, Biogen intends to evaluate felzartamab for IgA nephropathy and membranous nephropathy, while simultaneously launching two undisclosed Phase II proof-of-concept studies investigating anti-CD38 mechanisms in autoantibody-driven conditions outside the renal space.

Biogen has further expanded its commercial and clinical infrastructure through transactions involving Apellis Pharmaceuticals, integrating market-ready products such as Syfovre alongside specialized nephrology sales and medical capabilities designed to support future product rollouts. Keeney pointed to geographic atrophy—the primary indication for Syfovre—as a substantially underpenetrated therapeutic market where long-term commercial success will depend on driving initial patient diagnosis and ensuring ongoing treatment adherence. To capitalize on this opportunity, Biogen is considering direct-to-consumer outreach campaigns to educate patients and clinicians on the benefits of early medical intervention.

To fund these clinical initiatives while maintaining fiscal discipline, Biogen is implementing its "Fit for Growth" restructuring program aimed at optimizing its global cost structure. Kramer explained that the cost-alignment initiative redirects capital away from older multiple sclerosis programs toward high-conviction research projects and commercial launches. Biogen projects it will achieve roughly $250 million in annualized operational savings upon exiting next year. The workforce and spending reductions will primarily target research and development alongside general and administrative divisions, while direct sales teams and medical field organizations will remain largely untouched.

On the capital structure front, management expects the Apellis transaction to weigh on earnings in 2026, driven primarily by interest expenses linked to deal financing. However, Kramer stated that Biogen plans to fully pay down its acquisition-related debt obligations by the end of 2027. Meanwhile, the company's legacy multiple sclerosis drug Tysabri has demonstrated revenue resilience against entering biosimilars, supported by strong physician preference, established patient support services, an FDA-cleared JCV diagnostic assay, and a subcutaneous formulation offered in international markets.

Biogen also continues to extract steady cash flow from its long-standing corporate partnerships and rare disease portfolio. Kramer noted that partner Roche recently debuted a subcutaneous version of Ocrevus, yielding ongoing royalty streams for Biogen alongside existing profit-sharing arrangements for Rituxan and Gazyva—the latter of which earned regulatory approvals for lupus nephritis in both the U.S. and Europe this year. In spinal muscular atrophy, patient volumes for Spinraza, developed alongside Ionis Pharmaceuticals, have stabilized as clinicians transition individuals to higher-dosage regimens. Biogen plans to reduce administration friction for Spinraza by deploying acquired device technology from Alcyone, which utilizes an implanted port system to deliver intrathecal therapies without requiring routine spinal taps.

Looking toward 2027, Keeney outlined a corporate development strategy focused primarily on earlier-stage licensing and acquisition opportunities across rare diseases, immunology, and neurology. Rather than chasing unvalidated biological concepts, Biogen is prioritizing clinical programs characterized by established Phase III trial parameters, clear regulatory pathways, and validated clinical endpoints. While the company remains financially flexible for smaller early-stage transactions in the near term, executives indicated that larger-scale mergers and acquisitions could re-enter consideration as Biogen strengthens its balance sheet over the coming year.